IP Library Granted Patent US 9,834,820
Granted Patent B2
US 9,834,820 · App. 14/577,177 · Granted Dec 5, 2017

Methods for the treatment and diagnosis of bone mineral density related diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,834,820
App. No.
14/577,177
Granted
Dec 5, 2017
Kind
B2
Abstract

Described herein are methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, described herein are methods of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of such a mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. Also described are compounds such as a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). Additional aspects describe an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).

Claims (2)

1. A method for treating a disease associated with a decreased bone mineral density comprising administering to a subject in need thereof a compound selected from the group consisting of a thromboxane synthase inhibitor and a thromboxane receptor antagonist, wherein said disease associated with decreased mineral density is osteogenesis imperfecta.

2. The method of claim 1 , wherein said thromboxane synthase inhibitor or thromboxane receptor antagonist is selected from the group consisting of Ozagrel, Seratrodast and Picotamide.

Assignments (4)
CHANGE OF NAME Recorded May 12, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059988/0388 →
MERGER Recorded May 12, 2022
From: UNIVERSITE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 060044/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2017
From: CORMIER-DAIRE, VALERIE; MUNNICH, ARNOLD
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Reel/Frame 043151/0838 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2017
From: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS DESCARTES; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
Reel/Frame 042931/0822 →